BETA: Please send your feedback!
Neurocrine Biosciences
NBIX:NAS
Biotechnology
—
MID cap
(—)
—
since start of 2022
—
About
Biotechnology
Founded 1992
Neurocrine Biosciences, Inc. operates as a product based biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale on January, 1992 and is headquartered in San Diego, CA.
website
Headquarters
Executives
| Name | Title | Gender |
| Errol B. de Souza, PhD | Founder | Male |
| Kevin Charles Gorman, PhD, MBA | Chief Executive Officer & Director | Male |
| Christopher Flint O'Brien, MD | Chief Medical Officer | Male |
| Darin M. Lippoldt | Chief Legal Officer | Male |
| William H. Rastetter, PhD | Chairman | Male |
| Paul W. Hawran, CPA | Founder | Male |
| Wylie W. Vale, PhD | Founder | Male |
| Dimitri E. Grigoriadis, PhD | Chief Research Officer | Male |
| Bill Wilson | Vice President-Information Technology & Operations | Male |
| Malcolm Lloyd-Smith | Chief Regulatory Officer | Male |
| Jane Sorensen | Head-Investor Relations | Female |
| David-Alexandre C. Gros, MD, MBA | President, Chief Operating & Financial Officer | Male |
Mindful Investing Summary
Neurocrine Biosciences - Competitors and Related Companies
How Neurocrine Biosciences stacks up to its peers in the Biotechnology industry or with competing business segments.
Neurocrine Biosciences
NBIX:NAS
Biotechnology
—
MID cap
(—)
—
since start of 2022
—
Paratek Pharmaceuticals
PRTK:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2022
—
AbbVie
ABBV:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2022
—
Eli Lilly
LLY:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2022
—
CASI Pharmaceuticals
CASI:NAS
Biotechnology
—
MICRO cap
(—)
—
since start of 2022
—
Palatin Technologies
PTN:ASE
Biotechnology
—
MICRO cap
(—)
—
since start of 2022
—